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Introduction
Non-adherence to medication remains a significant barrier to improved health outcomes [1] .
Adherence is a complex behaviour that is influenced by many factors [1, 2] . There is a large amount of literature suggesting some of the key factors that may be involved in medication adherence and these include age, patient-physician relationship, condition-related factors and patient-related factors [1] . Patient-related factors play a strong role and include the beliefs or perceptions individuals hold about their treatment, their illness and the health-care system [1] [2] [3] . Particular focus has been placed on the relationship between medication adherence and the beliefs that a person holds towards their medicines [2, 4] . Medication beliefs most clearly influence adherence when medication non-adherence is not accidental or random, but rather a decision made by the patient to take their medicines in a different way [5] . Medication beliefs are also likely to play a role when there are other factors influencing the patient's adherence, such as the symptoms the patients is experiencing, or when making decisions regarding altering their dose to reduce side effects or using their medicines sparingly because of financial reasons [6, 7] .
The Beliefs about Medicines Framework is derived from the Health Belief Model, which describes how beliefs about medicines might affect medication-taking behaviour [4] . The Health Belief Model proposes that an individual chooses a particular behaviour through a costbenefit analysis where the perceived benefits (e.g. improvements in health) are balanced against the perceived costs (e.g. physical pain, loss of time) [8] [9] [10] .
A number of tools exist to elicit medication beliefs, including the Brief Medication Questionnaire [11] , The Adherence Estimator [12] and the Beliefs and Behaviour Questionnaire [13] . The most widely used tool is the Beliefs about Medicines Questionnaire (BMQ) which stems directly from the Beliefs about Medicines Framework [14, 15] . The BMQ has two subscale domains: necessity and concerns. A high score on the necessity subscale suggests an individual has strong beliefs in the necessity of their medicine and a high score on the concerns subscale suggests the individual has strong concerns about the negative effects of taking medicines [4, 14] . Necessity beliefs were thought to promote adherence, while concern beliefs were thought to hinder adherence [4] .
Another method of relating medication beliefs to medication is by subtracting the BMQ concern score from the BMQ necessity score to generate a necessity-concerns differential. A positive score indicates the individual has stronger beliefs in the necessity of medication relative to concerns [4] . The necessity-concerns differential is an important aspect of the Beliefs about Medicines Framework as it is a method of illustrating the cost-benefit analysis individuals make in their adherence-related decisions as described in the Health Belief Model [4] .
Scores from the BMQ have been correlated to medication adherence across a number of different conditions including asthma [16] [17] [18] [19] [20] [21] , cardiovascular disease [22] [23] [24] [25] [26] [27] , mental illness [28] [29] [30] [31] and cancer [32] [33] [34] . Of the papers relating beliefs about medicines to a measure of medication adherence, some report only necessity beliefs are correlated to medication adherence [19, 21, 22, [35] [36] [37] [38] while others have found only concern beliefs to be correlated to medication adherence [30, [39] [40] [41] [42] [43] . In some studies, the necessity-concerns differential was shown to have a stronger correlation with adherence than necessity or concern beliefs alone [4, 20, 44, 45] . From these findings, it is unclear whether each of these scales -necessity, concerns and the necessity-concern differential -correlate with adherence on a population level. A recently published meta-analysis by Horne and colleagues [46] found the relationship between necessity and concern beliefs and medication adherence remained significant when stratified by country published, sample size and type of adherence measure used. It was not clear in their post-hoc analysis whether this relationship was different between patient conditions.
It is important to confirm whether in specific conditions the relationship between necessity and concern beliefs and medication adherence is changed. Each condition has its unique set of challenges, which can be due to the use of different medicines, symptoms of the condition or treatment, expected or actual outcomes and how it affects an individual's quality of life. All these factors can affect the way in which an individual conceptualises their condition, its associated symptoms, the treatment and treatment outcomes [47] . Given these distinct differences between illnesses, it would be expected that the way necessity, concerns and/or the necessity-concerns differential correlate to adherence is also different. The condition in itself may be one variable that influences how medication beliefs affect an individual's adherence.
By exploring whether the condition an individual has impacts the relationship between medication adherence and necessity and concern beliefs may improve our understanding in this area.
This meta-analysis investigated whether necessity beliefs, concern beliefs and the necessityconcerns differential are associated with medication adherence on a population level. We also set out to assess whether the correlation between BMQ subscales and adherence varied across different conditions. This study also provides an opportunity to extend the findings presented by Horne and colleagues [46] who did not assess the relationship between the necessityconcerns differential and adherence.
Method
This study was conducted and prepared in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement [48] .
Eligibility criteria
Peer-reviewed manuscripts indexed in Web of Science, EMBASE, PubMed or CINAHL utilising the BMQ were included if they were full text original research published in English, participants were aged 18 years or older and the paper reported the relationship between any measure of adherence and beliefs about medicines. All study designs were included. Studies that changed, added or removed questions from the BMQ without evidence of questionnaire validation were excluded. We also excluded validation studies, protocols and conference abstracts. Results that could not be accurately converted to the common effect size by either calculation or through personal communication with the authors were also excluded. 
Search strategy

Study Selection
The first author (HF) screened all retrieved studies for eligibility. To ensure the screening process was accurate and reproducible, a second author (ALC) independently screened 10% of all retrieved studies.
Data extraction
The coding was undertaken using a structured table. The items extracted from the studies included: sample size, illness population, method of assessing adherence, study design, statistics used and reported findings. We contacted 28 authors for additional information. Eight authors did not reply and six authors could not provide any further unpublished information.
Meta-analysis
R Studio software version 3 was used for all statistical analyses in the review. The metaanalysis tested the association between medication adherence and three BMQ-related scales: 1) necessity subscale, 2) concern subscale and 3) necessity-concern differential score.
Pearson's correlation (r) was chosen for the common effect size as it best represents the strength and direction of association between the two continuous variables. In some manuscripts, the correlation was not directly reported and needed to be estimated from other reported data using standard methods [49] . If this was not possible, authors were contacted to obtain the appropriate data. Pearson's correlation was transformed into Fisher's z for each study before combining studies. This approach is recommended to give a more symmetrical data set [49] . All results reported in the paper have been transformed back to r for ease of interpretation.
Some studies reported more than one effect size (e.g. effect size at two time points). To ensure that each effect size in the meta-analysis was independent of each other, only one effect size from each study was used. For papers that reported multiple time points, the baseline results were chosen to prevent the influence of the study intervention. In non-interventional longitudinal studies that included initiation of a medication the later time point was chosen. An individual's response to the BMQ may be different at medication initiation compared to later time points. Including data from later time points for non-interventional longitudinal studies ensures that the included data is more comparable to the other studies included in the meta-analysis. If more than one adherence measure was used and there was no missing data from either measure, the mean correlation between the two was reported. This was done because all measures of adherence were deemed relevant to the study aim and most importantly, to avoid non-independence [49] . If missing data existed, only the measure with full results was included in the analysis. If results were separated based on certain characteristics (e.g. gender), a weighted mean correlation was calculated to ensure that the subgroup with the larger sample size received more weighting. Lastly, when multiple subgroups were involved and individuals could be in more than one group (i.e. subgroups based on prescribed medicines and the individual was on more than one prescribed medicine), the group with the largest sample size was chosen.
The random-effects model was used in the meta-analysis because of the expected heterogeneity between studies and to provide a more conservative approach [49] . The random-effects model accounts for within-study variance and between-study variance (tau-squared [τ 2 ]). Hedges Ԛ test was used to test for the existence of heterogeneity and the I 2 index was used to evaluate the amount of heterogeneity between studies [49] .
Funnel plots were examined visually and formally with Egger's test to evaluate the effect of publication bias in the meta-analysis [50].
Assessment of risk of bias within studies
The effect size was examined according to each of the following quality components: measure of adherence, power and study design.
Measures of adherence were categorised as either objective (e.g. Medication Event Monitoring System [MEMS], prescription refills), validated self-report method or unvalidated self-report method. Measures of adherence that were categorised as 'validated self-report method' were questionnaires that had previously shown evidence of some form of validation, such as previously being compared to objective measures of adherence (e.g. MAQ [51] ). In comparison, measures categorised as 'unvalidated' had no evidence of validation. These were often study-specific measures or had added/removed questions of established questionnaires (e.g. adding questions to the MAQ). Studies that used more than one measure of adherence were classified as mix.
Studies with 85 or more participants were categorised as having high power. Studies with less than 85 participants were categorised as having low power. This sample size differentiation was based on the ability of the sample to detect a medium effect size correlation (0.3) with alpha value of 0.05 and 80% power.
Lastly, cross-sectional studies were compared to those with a longitudinal design.
Sub-group analysis
To explore differences in effect size, the analysis was stratified by condition. Studies that used participants without a defined illness were excluded from the analysis. Differences in effect sizes between conditions were assessed by comparing 95% confidence intervals between each condition and with the overall effect size.
Results
Study Selection
A total of 3607 records were identified through database searches. Eleven additional records were found through bibliographies of identified studies. 3206 records were excluded after removing duplicates and screening titles and abstracts of studies for relevance. This left 412
full-text records that were assessed for eligibility. Of these papers, 318 papers were excluded.
Reasons for exclusion are provided in figure 1 . This left 94 papers published between 1999 and 2015 to be included in the meta-analysis. Of the 94 papers analysed, 91 were able to be included in the necessity meta-analysis, 89 in the concerns meta-analysis and 25 papers in the necessity-concerns differential meta-analysis.
Study Characteristics
Characteristics of the included studies are shown in Table 1 . The studies differed substantially in sample size, patient population, study design and adherence measure. Sample sizes ranged from 33 to 1871 participants (mean=256, median=181). The majority of the studies were crosssectional (k=83). The most common conditions studied were cardiovascular disease (k=16) and mental illness (k=14). Nine studies enrolled participants with a diverse range of chronic diseases and most of these patients had multiple co-morbidities. There were 82 cross-sectional studies and 12 longitudinal studies included in the meta-analysis. Self-report was the main method of measuring adherence (k=87) with the Medication Adherence Report Scale (MARS) [52] most commonly used (k=17). Other methods used to measure adherence were prescription refill data (k =6), drug concentrations in the body (k=3) and MEMS (k=3). Seventeen studies used more than one measure of adherence (as recommended by the World Health Organisation [1] ). Seven studies used an altered version of the BMQ that had previously been validated.
Overall meta-analysis
All three variables in the meta-analysis showed significant associations with medication adherence as presented in Table 2 . The necessity subscale was positively correlated with medication adherence and the concerns subscale was negatively correlated with adherence. The necessity-concerns differential was also positively correlated with medication adherence. There was significant heterogeneity with all Ԛ values being statistically significant and all I 2 values indicated a large amount of heterogeneity between studies. Forest plots were produced for each variable, including the calculated overall effect size for each study. These are available online in the Supplementary data (Appendix B).
Funnel plots were produced to test for publication bias and these can be found in the Supplementary data (Appendix C). Taking into account the large amount of study heterogeneity, all plots indicated acceptable plot symmetry, which suggests limited publication bias. Similarly Eggers test showed no indication of asymmetry for necessity (t (89) = -0.32, p=0.75) or concerns (t (87) = -0.38, p=0.70) effect sizes. Eggers test for necessity-concerns differential was significant (t(23) = 2.2, p=0.04) indicating asymmetry, however the small number of studies and large expected heterogeneity needs to be taken into account [49] .
Assessment of risk of bias within studies
Necessity
There were no significant differences in effect size correlation for the necessity subscale when studies were stratified based on measure of adherence (p=0.39), power (p=0.31) or study design (p=0.47). Although effect sizes varied with each quality measure, as shown in Table 3 , all remained significant at p<0.05 and had confidence intervals which crossed that of the overall effect size seen in the meta-analysis.
Concerns
There was a significant difference in effect size correlation for the concerns subscale when studies were stratified based on measure of adherence (p=0.0002), with studies using objective measures of adherence having a significantly lower effect size correlation than any other measure of adherence (Table 4 ). There was no significant difference in effect size correlation when studies were stratified based on power (p=0.73) or study design (p=0.58). All other effect sizes remained significant at p<0.05 and had confidence intervals which crossed that of the overall effect size seen in the meta-analysis.
Stratifying by condition
Stratifying the analysis by condition showed that the effect of necessity and concern beliefs on adherence varied in some conditions. Table 5 provides the effect size correlations for condition group. We assessed variability in effect sizes in each subscale by comparing the 95% confidence interval for the condition against 95% confidence interval of the aggregated results.
Non-overlapping confidence intervals were observed for necessity beliefs in asthma and cardiovascular disease (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure).
Specifically, the correlation was higher in studies conducted in asthma (COR=0.33) and lower in cardiovascular disease (COR=0.07), compared to the overall effect size for all included studies. No differences between different condition groups were observed in effect sizes for concern beliefs. A number of conditions did not have an enough studies to examine condition related differences and this limits our interpretation of the data. Similarly, for the necessityconcerns differential there were limited studies to make any condition specific conclusions.
Discussion and Conclusion
Discussion
This study reports on a meta-analysis to determine if beliefs about medicines elicited by the BMQ are correlated to medication adherence at a population level. We found that both necessity and concern beliefs were significantly correlated with medication adherence on a population level. The small but significant correlations reported in this meta-analysis indicate that adherence to medication is positively correlated with necessity beliefs and negatively correlated with concern beliefs elicited from the BMQ. Those who believe their medication is necessary for their current and future health are more likely to be adherent to their medication than those who do not endorse these beliefs. Conversely, individuals who hold strong concern beliefs, such as beliefs about side effects, dependence on medicines and disruption to daily life are more likely to be non-adherent to their medication. The results of the meta-analysis also found that having stronger beliefs in necessity relative to concerns, as measured by the necessity-concerns differential was positively correlated with medication adherence on a population level. Only 25 (27%) of the included studies in the metaanalysis reported using the necessity-concerns differential. The differential is an indicator of the relative importance of necessity and concern beliefs for an individual and a method of operationalising the cost-benefit analysis described by the Health Belief Model [4, 15] . The differential appears useful to understand the interplay between necessity and concern beliefs and the 'cost-benefit' decisions individuals are making with their medicines [4] . Our study is the first to show that across many different conditions, the necessity-concern differential is significantly correlated with medication adherence. We suggest that the necessity-concerns differential should be used more in research as a way of presenting the cost-benefit analysis individuals are making.
For the majority of conditions included in the meta-analysis, beliefs were related to adherence in a way that is consistent with the Beliefs about Medicines Framework. This in itself is striking given the wide variety of conditions included in the meta-analysis. The only two conditions that had correlations in which their 95% confidence interval did not overlap with aggregated results was in asthma and the cardiovascular group (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure). In studies conducted in asthma, there was a stronger overall effect size between necessity beliefs and medication adherence. This suggests that for these individuals, having a high score on the necessity subscale is a stronger correlate of adherence than the overall population. Menckeberg and colleagues [18] found that patients with asthma who had strong necessity beliefs reported the highest medication adherence, regardless of whether they had strong or weak concern beliefs. Adherence to asthma medicines may be dependent on patients believing in the necessity of their medicines for current and future health, given the chronicity and asymptomatic nature of asthma. In comparison, the cardiovascular group (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure) showed no correlation between necessity beliefs and adherence. Patients with more severe cardiovascular disease, such as those who have had a stroke often express concerns that they are prescribed too many medicines and medicines can give bad side effects without any symptomatic benefit or making them feel any better [60, 119] . It appears that the relationship between medication adherence and concern beliefs is stronger than the relationship with necessity beliefs in patients with cardiovascular disease (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure). This may mean that addressing concern beliefs is a more important target for researchers to focus interventions on in order to support medication adherence in these patient populations.
In comparing the results of the present meta-analysis to the previous meta-analysis conducted by Horne and colleagues [46] , there were some differences in the included studies. Nineteen studies included in the previous meta-analysis were not included in the present study because of different inclusion/exclusion criteria or being unable to calculate an effect size from available data. Conversely, we included an additional 21 studies that were not included in the previous meta-analysis. The majority of these studies were published after the previous metaanalysis. Despite these differences, our findings are in line with the meta-analysis conducted by Horne and colleagues.
An interesting finding of our quality assessment analysis is that in studies using an objective measure of adherence, there was a significantly lower mean concern effect size compared to other measures of adherence. It is noteworthy that objective measures not only included MEMS, but also prescription refills and drug concentrations in the body. The reason for the difference in effect size is not clear. There were a small number of studies included in this category (k=7); however, a number of these had large sample sizes. It may be that the statements/questions in self-report adherence questionnaires more closely align with the statements in the BMQ and therefore participants' answers are likely to align and result in a stronger correlation. This appears to be an interesting area to explore in future research.
Limitations
A number of conditions such as migraine and ulcerative colitis had insufficient sample size. This limited our ability to make any inferences about differences in effect sizes. An inherent problem among many meta-analyses is that not all included studies reported results as the common effect size (i.e. correlation). While standard equations were used to convert individual study results into correlations, it is likely that the converted correlation is an underestimation of the true effect size. Our findings are conservative and as such, the true effect size for the three variables may be larger than reported.
Conclusion
This meta-analysis supports the use of the Beliefs about Medicines framework for predicting medication adherence and the BMQ as an effective tool to elicit beliefs in the necessity and concerns of medications across diverse conditions. We found that for the majority of conditions, holding strong beliefs in the necessity of medication and weak concern beliefs were predictive of medication adherence. Although the necessity-concerns differential was not commonly used in the included studies, our analysis indicated that it was also a positive predictor of adherence. Stratification by condition was limited by some groups having small sample sizes; however, we identified that in asthma and in the cardiovascular group (ACS/Stroke/Coronary Artery Bypass Surgery/Heart Failure), the relationship between necessity beliefs and medication adherence was different compared to the overall effect size.
Practice Implications
Given the multifactorial nature of adherence, our research suggests that necessity and concern beliefs about medicines are an important factor to consider when understanding reasons for non-adherence. We suggest that the differences in necessity effect size observed in asthma and the cardiovascular group compared to the overall effect size should be further investigated as it may affect the content of future tailored interventions designed to improve medication adherence. This meta-analysis also highlights that further research in conditions such as migraine and ulcerative colitis is needed to be able to draw conclusions on the relationship between beliefs about medicines and medication adherence in these conditions.
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